+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06991101

Randomized Study Comparing Ruxolitinib Plus Radiation and Temozolomide to Radiation and Temozolomide Alone for Newly Diagnosed Glioblastoma

Led by Baptist Health South Florida · Updated on 2026-10-02

190

Participants Needed

2

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of the investigational drug ruxolitinib when added to the standard treatment of radiation therapy and temozolomide for adults with newly diagnosed glioblastoma. This randomized phase 2 trial compares two groups one receiving ruxolitinib plus radiation and temozolomide, and the other receiving radiation and temozolomide alone. Participants are assigned to groups by chance to fairly assess the effects of adding ruxolitinib. The study includes two phases of drug administration during radiation therapy and a maintenance phase after radiation ends. Ruxolitinib is taken orally twice daily during radiation for six weeks, followed by a 4-week break, then continued in 28-day cycles until disease progression or intolerance. Temozolomide is also taken orally daily during radiation, then in cycles during maintenance. Radiation therapy is given every weekday for six weeks. Dose adjustments may occur if side effects develop. Participants will be monitored throughout the study with assessments including overall survival at four years as the primary outcome. Additional measures include survival rates at earlier times, progression-free survival, response rates, adverse events, mortality, and lab abnormalities. The study lasts up to four years, with regular follow-ups to evaluate treatment effects and safety.

CONDITIONS

Brief Title

Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

Research Team

M

Manmeet Ahluwalia, M.D., MBA

W

WCI Multisite Research Program

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here